Results 31 to 40 of about 14,439 (224)

Potential Cost-Savings From the Use of the Biosimilars in Slovakia

open access: yesFrontiers in Public Health, 2020
Objectives: To analyse the market shares of biosimilars in Slovakia and to calculate the potential cost-savings from the use of biosimilars in Slovakia based on two different data sources.Methods: National reimbursement lists from the Czech Republic ...
Tomas Tesar   +6 more
doaj   +1 more source

Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey

open access: yesFrontiers in Pharmacology, 2022
Objective: With increasing numbers of biosimilars entering the market or in the approval pipeline in China, understanding the current awareness and attitudes of biosimilars still remains the first step to promote uptake.
Yang Hu   +17 more
doaj   +1 more source

Biosimilar insulins in international and domestic practice of pharmacist

open access: yesФармацевтичний журнал, 2022
In Ukraine, people with diabetes receive insulin, including insulin biosimilars in pharmacies, so pharmacists should increase their knowledge about biosimilar because they become more available in the coming years. The aim of the work was to summarize
I. O. Vlasenko, I. V. Nizhenkovska
doaj   +1 more source

Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective [PDF]

open access: yesGlobal Journal on Quality and Safety in Healthcare, 2020
Biologics are significant drivers of globally escalating healthcare costs. Biosimilars have potential to offer cost savings with comparable efficacy and safety to innovator products and increase the access of treatment to more patients.
Mansoor A. Khan   +4 more
doaj   +1 more source

T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia

open access: yesBlood Advances, 2017
: Immunogenicity of biotherapeutics and the elicitation of anti-drug antibodies are a key concern for their efficacy, pharmacokinetics, and safety.
Tina Rubic-Schneider   +11 more
doaj   +1 more source

Etanercept biosimilars [PDF]

open access: yesRheumatology International, 2014
Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F.   +4 more
openaire   +2 more sources

Physicians’ perceptions of the uptake of biosimilars: a systematic review

open access: yesBMJ Open, 2020
Objectives To examine physicians’ perceptions of the uptake of biosimilars.Design Systematic review.Data sources MedLine Ovid and Scopus databases at the end of 2018.Eligibility criteria Original scientific studies written in English that addressed ...
Katri Hämeen-Anttila   +3 more
doaj   +1 more source

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019

open access: yesPharmaceuticals, 2021
Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System ...
Manuel García-Goñi   +3 more
doaj   +1 more source

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

open access: yesArthritis Research & Therapy, 2019
Background ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).
Stanley Cohen   +7 more
doaj   +1 more source

The structure-function relationship of disulfide bonds in etanercept

open access: yesScientific Reports, 2017
Etanercept is a TNFα receptor Fc fusion protein used for the treatment of rheumatic disease and psoriasis. Physicochemical and functional investigation of process fractions during development of the etanercept biosimilar GP2015 (Erelzi®) revealed a ...
William C. Lamanna   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy